Overview

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Status:
Terminated

Trial end date:
2010-06-01

Target enrollment:
0

Participant gender:
All

Summary

This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

ICON Bioscience Inc

Criteria

Inclusion Criteria:

- Male or female patients 40 years of age scheduled for unilateral cataract surgery
(phacoemulsification or extracapsular extraction) with posterior chamber intraocular
lens implantation.

Exclusion Criteria:

- Patients who have used any ocular, topical or oral corticosteroids within 7 days prior
to Day 0.

- Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to
screening.

- Patients with any signs of intraocular inflammation in either eye at screening.

- Patients who have received any prior intravitreal injections in the study eye.